Press Releases

Press Releases

View all news
Voronoi's Pulmonary Arterial Hypertension Therapy Selected for Korea Drug Development Fund Project
2022.11.07
⚫ Inhibitor of pulmonary arterial smooth muscle proliferation, the cause of pulmonary arterial hypertension, shows 'excellent safety and efficacy'

Voronoi (CEOs Daekwon Kim and Hyuntae Kim), a global drug design company, announced on the 7th that 'VRN13,' which it is developing as an inhaled therapy for pulmonary arterial hypertension, has been selected as a new drug R&D ecosystem building research support project by the Korea Drug Development Fund (KDDF, Director Hyunsang Mook).

With this selection for the Korea Drug Development Fund project, Voronoi will receive two years of R&D funding for the derivation of a drug candidate for VRN13.

VRN13 is a targeted therapy that selectively inhibits the proliferation of pulmonary arterial smooth muscle, the cause of pulmonary arterial hypertension, and maximizes safety and efficacy by minimizing its effect on the other cells that make up the lung besides pulmonary arterial smooth muscle. Because a compound previously tested in clinical trials by another company failed to obtain approval due to systemic toxicity that occurred with oral administration, VRN13 is being developed as an inhaled formulation so that it acts locally in the lung and maximizes therapeutic efficiency.

CEO Daekwon Kim of Voronoi said, "The selection for the Korea Drug Development Fund project allows us to accelerate R&D on VRN13. We plan to derive the final drug candidate next year."

Based on its unrivaled drug design technology, Voronoi has developed numerous compounds with exceptionally high selectivity and blood-brain-barrier penetration, completing a total of five license-out deals from 2020 through this year, including four license-out deals to the U.S. Its cumulative license-out track record amounts to KRW 3.18 trillion (USD 2,272.7 million, based on an exchange rate of KRW 1,400 per U.S. dollar).